
Bio-Techne (TECH) Stock Forecast & Price Target
Bio-Techne (TECH) Analyst Ratings
Bulls say
Bio-Techne is a well-established life sciences manufacturer with a strong foothold in the pharma, biotech, academic, and diagnostic markets. With a diverse product portfolio, strong sales in the US and international markets, and a strategic focus on sustainability and human capital management, the company is well-positioned for long-term growth potential. Additionally, the pending acquisition of Wilson Wolf could further boost sales and solidify Bio-Techne's position as a leader in the cell therapy market. While there are potential risks to consider, such as potential market downturns and competition from larger companies, we believe that Bio-Techne's strong financials and strategic initiatives make it a solid investment for the future.
Bears say
Bio-Techne is facing potential downsides and concerns including acquisition risks, competition and share loss, reliance on cell therapy development, and potential decrease in demand for wet lab work due to advancements in dry lab technology. Though the company is aggressively improving business operations and has the potential for long-term growth through the Wilson Wolf acquisition, the current proposed takeout price by Merck KGaA at $73 is likely to close. However, the lack of science-based emissions targets raises concerns about the company's sustainability efforts.
This aggregate rating is based on analysts' research of Bio-Techne and is not a guaranteed prediction by Public.com or investment advice.
Bio-Techne (TECH) Analyst Forecast & Price Prediction
Start investing in Bio-Techne (TECH)
Order type
Buy in
Order amount
Est. shares
0 shares